Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2004 Jan;50:65–72.

What's a man to do? Treatment options for localized prostate cancer.

Tom Pickles 1
PMCID: PMC2214501  PMID: 14761106

Abstract

OBJECTIVE: To describe treatments for localized prostate cancer: surgery, external radiation therapy, and brachytherapy; watchful waiting might also be appropriate. Patients trying to decide about treatment ask family physicians for advice. This article sets out a framework to aid patients (and physicians) in the decision. QUALITY OF EVIDENCE: Only two randomized studies comparing different treatments were identified. Because of the paucity of level I or II evidence, suggestions in this review are largely based on expert opinion and consensus statements. MAIN MESSAGE Risk-grouping and nomograms are useful for assessing treatments and estimating outcomes of treatment. Where treatments are equivalent, decisions can be based on perception of toxicity and convenience. Effects on patients'lives and on sexual, urinary, and bowel function vary by treatment modality. CONCLUSION: Men with low-risk prostate cancer should decide on treatment based on their perception of how treatment will affect their lives. Men with higher-risk cancers might accept adverse effects on their quality of life in return for longer survival.

Full Text

The Full Text of this article is available as a PDF (294.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akakura K., Isaka S., Akimoto S., Ito H., Okada K., Hachiya T., Yoshida O., Arai Y., Usami M., Kotake T. Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology. 1999 Aug;54(2):313–318. doi: 10.1016/s0090-4295(99)00106-5. [DOI] [PubMed] [Google Scholar]
  2. Albertsen P. C., Hanley J. A., Gleason D. F., Barry M. J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):975–980. doi: 10.1001/jama.280.11.975. [DOI] [PubMed] [Google Scholar]
  3. Begg Colin B., Riedel Elyn R., Bach Peter B., Kattan Michael W., Schrag Deborah, Warren Joan L., Scardino Peter T. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002 Apr 11;346(15):1138–1144. doi: 10.1056/NEJMsa011788. [DOI] [PubMed] [Google Scholar]
  4. Bolla Michel, Collette Laurence, Blank Léo, Warde Padraig, Dubois Jean Bernard, Mirimanoff René-Olivier, Storme Guy, Bernier Jacques, Kuten Abraham, Sternberg Cora. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002 Jul 13;360(9327):103–106. doi: 10.1016/s0140-6736(02)09408-4. [DOI] [PubMed] [Google Scholar]
  5. Bucci Joseph, Morris W. James, Keyes Mira, Spadinger Ingrid, Sidhu Sabeena, Moravan Veronika. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):91–98. doi: 10.1016/s0360-3016(01)02812-7. [DOI] [PubMed] [Google Scholar]
  6. Choo Richard, Klotz Laurence, Danjoux Cyril, Morton Gerard C., DeBoer Gerrit, Szumacher Ewa, Fleshner Neil, Bunting Peter, Hruby George. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002 Apr;167(4):1664–1669. [PubMed] [Google Scholar]
  7. Crawford E. D., Bennett C. L., Stone N. N., Knight S. J., DeAntoni E., Sharp L., Garnick M. B., Porterfield H. A. Comparison of perspectives on prostate cancer: analyses of survey data. Urology. 1997 Sep;50(3):366–372. doi: 10.1016/s0090-4295(97)00254-9. [DOI] [PubMed] [Google Scholar]
  8. Crook J., Lukka H., Klotz L., Bestic N., Johnston M., Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ. 2001 Apr 3;164(7):975–981. [PMC free article] [PubMed] [Google Scholar]
  9. Davison B. Joyce, Gleave Martin E., Goldenberg S. Larry, Degner Lesley F., Hoffart Doug, Berkowitz Jonathan. Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nurs. 2002 Feb;25(1):42–49. doi: 10.1097/00002820-200202000-00009. [DOI] [PubMed] [Google Scholar]
  10. Grimm P. D., Blasko J. C., Sylvester J. E., Meier R. M., Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):31–40. doi: 10.1016/s0360-3016(01)01601-7. [DOI] [PubMed] [Google Scholar]
  11. Holmberg Lars, Bill-Axelson Anna, Helgesen Fred, Salo Jaakko O., Folmerz Per, Häggman Michael, Andersson Swen-Olof, Spångberg Anders, Busch Christer, Nordling Steg. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002 Sep 12;347(11):781–789. doi: 10.1056/NEJMoa012794. [DOI] [PubMed] [Google Scholar]
  12. Hu Jim C., Gold Karen F., Pashos Chris L., Mehta Shilpa S., Litwin Mark S. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol. 2003 Feb 1;21(3):401–405. doi: 10.1200/JCO.2003.05.169. [DOI] [PubMed] [Google Scholar]
  13. Hu Jim C., Gold Karen F., Pashos Chris L., Mehta Shilpa S., Litwin Mark S. Temporal trends in radical prostatectomy complications from 1991 to 1998. J Urol. 2003 Apr;169(4):1443–1448. doi: 10.1097/01.ju.0000056046.16588.e4. [DOI] [PubMed] [Google Scholar]
  14. Kattan Michael W., Scardino Peter T. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer. 2002 Sep;1(2):90–96. doi: 10.3816/cgc.2002.n.010. [DOI] [PubMed] [Google Scholar]
  15. Klotz L., Gleave M., Goldenberg S. L. Neoadjuvant hormone therapy: the Canadian trials. Mol Urol. 2000 Fall;4(3):233–239. [PubMed] [Google Scholar]
  16. Klotz Laurence H., Fradet Yves. Controversies in the management of localized prostate cancer: consensus development by Canadian urologists. Can J Urol. 2002 Jun;9 (Suppl 1):30–35. [PubMed] [Google Scholar]
  17. Kupelian Patrick A., Elshaikh Mohamed, Reddy Chandana A., Zippe Craig, Klein Eric A. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002 Aug 15;20(16):3376–3385. doi: 10.1200/JCO.2002.01.150. [DOI] [PubMed] [Google Scholar]
  18. Lawton C. A., Winter K., Murray K., Machtay M., Mesic J. B., Hanks G. E., Coughlin C. T., Pilepich M. V. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):937–946. doi: 10.1016/s0360-3016(00)01516-9. [DOI] [PubMed] [Google Scholar]
  19. Lee W. R., Hall M. C., McQuellon R. P., Case L. D., McCullough D. L. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):614–623. doi: 10.1016/s0360-3016(01)01707-2. [DOI] [PubMed] [Google Scholar]
  20. Litwin M. S., Lubeck D. P., Henning J. M., Carroll P. R. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol. 1998 Jun;159(6):1988–1992. doi: 10.1016/S0022-5347(01)63222-1. [DOI] [PubMed] [Google Scholar]
  21. Lukka H., Warde P., Pickles T., Morton G., Brundage M., Souhami L., Canadian GU Radiation Oncologist Group Controversies in prostate cancer radiotherapy: consensus development. Can J Urol. 2001 Aug;8(4):1314–1322. [PubMed] [Google Scholar]
  22. McLaren D. B., McKenzie M., Duncan G., Pickles T. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer. 1998 Jan 15;82(2):342–348. doi: 10.1002/(sici)1097-0142(19980115)82:2<349::aid-cncr15>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  23. Pickles Tom, Coldman Andy, Phillips Norm. The changing face of prostate cancer in British Columbia 1988-2000. Can J Urol. 2002 Jun;9(3):1551–1557. [PubMed] [Google Scholar]
  24. Pilepich M. V., Winter K., John M. J., Mesic J. B., Sause W., Rubin P., Lawton C., Machtay M., Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243–1252. doi: 10.1016/s0360-3016(01)01579-6. [DOI] [PubMed] [Google Scholar]
  25. Pollack A., Zagars G. K., Smith L. G., Lee J. J., von Eschenbach A. C., Antolak J. A., Starkschall G., Rosen I. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000 Dec 1;18(23):3904–3911. doi: 10.1200/JCO.2000.18.23.3904. [DOI] [PubMed] [Google Scholar]
  26. Potosky A. L., Legler J., Albertsen P. C., Stanford J. L., Gilliland F. D., Hamilton A. S., Eley J. W., Stephenson R. A., Harlan L. C. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000 Oct 4;92(19):1582–1592. doi: 10.1093/jnci/92.19.1582. [DOI] [PubMed] [Google Scholar]
  27. Ross P. L., Scardino P. T., Kattan M. W. A catalog of prostate cancer nomograms. J Urol. 2001 May;165(5):1562–1568. [PubMed] [Google Scholar]
  28. Ross Phillip L., Gerigk Claudia, Gonen Mithat, Yossepowitch Ofer, Cagiannos Ilias, Sogani Pramod C., Scardino Peter T., Kattan Michael W. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol. 2002 May;20(2):82–88. doi: 10.1053/suro.2002.32490. [DOI] [PubMed] [Google Scholar]
  29. Steineck Gunnar, Helgesen Fred, Adolfsson Jan, Dickman Paul W., Johansson Jan-Erik, Norlén Bo Johan, Holmberg Lars, Scandinavian Prostatic Cancer Group Study Number 4 Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002 Sep 12;347(11):790–796. doi: 10.1056/NEJMoa021483. [DOI] [PubMed] [Google Scholar]
  30. Talcott J. A., Clark J. A., Stark P. C., Mitchell S. P. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol. 2001 Aug;166(2):494–499. [PubMed] [Google Scholar]
  31. Weldon V. E., Tavel F. R., Neuwirth H., Cohen R. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol. 1995 May;153(5):1565–1569. [PubMed] [Google Scholar]
  32. Zelefsky M. J., Leibel S. A., Kutcher G. J., Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol. 1998 Apr;8(2):107–114. doi: 10.1016/s1053-4296(98)80006-4. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES